Skip to main content
Science & Medicine· Daily Pulse

The VA Is Testing Ozempic's Ingredient on Drinking. The Last Trial Says Watch the Heavy Days, Not the Craving.

Veterans Affairs has started a randomized trial of semaglutide for alcohol use disorder at nearly 20 medical centers. Two small trials so far found the drug didn't touch the measures researchers expected, and did cut the dangerous drinking days.

ByThe Rize NewsroomNovember 18, 20262 min readAlcohol

Somewhere in a VA hospital this month, a veteran who has tried to cut back on drinking a dozen times is getting a weekly injection, and neither the veteran nor the doctor knows whether it’s semaglutide, the active ingredient in Ozempic and Wegovy, or a placebo. The Department of Veterans Affairs has launched a randomized trial of the drug for alcohol use disorder at nearly 20 medical centers, from Houston and Seattle to Philadelphia and Long Beach. “Among substances of abuse, alcohol is one of the biggest problems among active military and our veterans,” said Christopher Verrico, the Baylor psychiatry researcher running the Houston site.

The question to ask about GLP-1 drugs isn’t whether they kill the craving. It’s whether they cut down the nights that put you in the ER.

That shift comes from the two small trials already done. In a Colorado study published this year in the American Journal of Psychiatry, 50 people seeking treatment took oral semaglutide or placebo for eight weeks. The main outcome, craving measured in a lab while people looked at alcohol cues, didn’t budge. Neither did drinks per day. What did change were heavy drinking days, drinks on the days people drank, everyday craving, and the harms people reported from their drinking. A 2025 JAMA Psychiatry trial of the weekly injection in 48 people who weren’t seeking treatment found the same pattern: no change in how many days people drank, but less drinking on the days they did.

In plain language, the drug seems to make people stop sooner once they start, more than it makes them not start. Biologically, that fits. GLP-1 drugs act on the brain’s reward circuitry, including the nucleus accumbens, which Verrico calls “a key part of the brain’s reward circuitry”. They seem to turn down the payoff of the next drink, not erase the wish for the first one. Both trials ran eight to nine weeks with about 50 people each, and most participants in the 2025 trial were women. The VA trial is the first big enough to say whether this holds for a mostly male, often trauma-exposed veteran population. The FDA wants at least 20% women in it.

If you’re a veteran who drinks, you don’t need to wait for this trial to finish. Naltrexone and acamprosate are approved for alcohol use disorder right now. Ask your VA prescriber for them by name, and if one doesn’t fit, ask about the other. If you’re a clinician seeing patients who are already on a GLP-1 drug for weight or diabetes, ask about their drinking at the next refill and write down what they say. That’s cheap evidence nobody is collecting.

We covered the off-label GLP-1 telehealth rush last month. The VA trial is what that market skipped: actually checking whether the drug works.

Filed Under

biologytreatmentscienceAlcoholVeteransClinical TrialPeer-Reviewed ResearchMAT — NaltrexoneAcamprosate

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section